14 research outputs found
Bifunctional PEGylated Exenatide-Amylinomimetic Hybrids to Treat Metabolic Disorders: An Example of Long-Acting Dual Hormonal Therapeutics
Peptide hybrids (phybrids) comprising
covalently linked peptide
hormones can leverage independent biological pathways for additive
or synergistic metabolic benefits. PEGylation of biologics offers
enhanced stability, duration, and reduced immunogenicity. These two
modalities can be combined to produce long-acting therapeutics with
dual pharmacology and enhanced efficacy. Compound <b>10</b> is
composed of an exenatide (AC2993) analogue, AC3174, and an amylinomimetic,
davalintide (AC2307), with an intervening 40 kD PEG moiety. It displayed
dose-dependent and prolonged efficacy for glucose control and body
weight reduction in rodents with superior <i>in vitro</i> and <i>in vivo</i> activities compared to those of a side-chain
PEGylated phybrid <b>6</b>. In diet-induced obese (DIO) rats,
the weight-loss efficacy of <b>10</b> was similar to that of
a combination of PEG-parents <b>3</b> and <b>4</b>. A
single dose of <b>10</b> elicited sustained body weight reduction
in DIO rats for at least 21 days. Compound <b>10</b>’s
terminal half-life of ∼27 h should translate favorably to weekly
dosing in humans
PK profile of orally dosed peptides in monkeys.
<p>[Leu<sup>14</sup>]exenatide-ABD (▾) and [Leu<sup>14</sup>]exenatide-ABP (▿), n = 3. Data are presented as mean ± SEM.</p
<i>In Vitro</i> Activity, Metabolic Stability, and Plasma Glucose in OGTT.
<p>Stability results (measured as plasma AUC 0–5 h; pancreatin mix AUC 0–2 h)) are expressed as a percentage of peptide remaining versus stable control peptide ± SEM. Replicates within each assay n = 3, except for exenatide and [Leu<sup>14</sup>]exenatide-ABP where n = 2.</p
Four-week chronic dosing of peptides in diabetic <i>Lep<sup>ob/ob</sup></i> Mice.
<p>(A) effects on HbA1c (B) effects on body weight and (C) effects on food intake. Vehicle (□), [Leu<sup>14</sup>]exenatide-ABD (▾) and exenatide (▪). Data are presented as mean ± SEM, n = 10. *p<0.05 vs. vehicle, #p<0.05 vs. exenatide infusion by ANOVA with Tukey’s test.</p
Functional activity at the GLP-1 receptor.
<p>GLP-1 (7–36) (▪), [Leu<sup>14</sup>]exenatide-ABD (▾) and [Leu<sup>14</sup>]exenatide-ABP (▿). GLP-1 (7–36) was used as a reference standard in the assay. The assay was run in quadruplicates and data are presented as mean ± SD. Abbreviations: Fluorescence (F).</p
Binding Constants for Albumin Interactions at 25°C.
<p>The number in parentheses represents the standard deviation in the last significant digit.</p
PK profile of intravenously dosed peptides in rats and monkeys.
<p>(A) rats, n = 3–4 and (B) monkeys, n = 3. Exenatide (▪), [Leu<sup>14</sup>]exenatide-ABD (▾) and [Leu<sup>14</sup>]exenatide-ABP (▿). Data are presented as mean ± SEM.</p
Improved Glucose Control and Reduced Body Weight in Rodents with Dual Mechanism of Action Peptide Hybrids
<div><p>Combination therapy is being increasingly used as a treatment paradigm for metabolic diseases such as diabetes and obesity. In the peptide therapeutics realm, recent work has highlighted the therapeutic potential of chimeric peptides that act on two distinct receptors, thereby harnessing parallel complementary mechanisms to induce additive or synergistic benefit compared to monotherapy. Here, we extend this hypothesis by linking a known anti-diabetic peptide with an anti-obesity peptide into a novel peptide hybrid, which we termed a phybrid. We report on the synthesis and biological activity of two such phybrids (AC164204 and AC164209), comprised of a glucagon-like peptide-1 receptor (GLP1-R) agonist, and exenatide analog, AC3082, covalently linked to a second generation amylin analog, davalintide. Both molecules acted as full agonists at their cognate receptors <i>in vitro</i>, albeit with reduced potency at the calcitonin receptor indicating slightly perturbed amylin agonism. In obese diabetic <i>Lep<sup>ob</sup>/Lep</i><sup><i>ob</i></sup> mice sustained infusion of AC164204 and AC164209 reduced glucose and glycated haemoglobin (Hb<sub>A1c</sub>) equivalently but induced greater weight loss relative to exenatide administration alone. Weight loss was similar to that induced by combined administration of exenatide and davalintide. In diet-induced obese rats, both phybrids dose-dependently reduced food intake and body weight to a greater extent than exenatide or davalintide alone, and equal to co-infusion of exenatide and davalintide. Phybrid-mediated and exenatide + davalintide-mediated weight loss was associated with reduced adiposity and preservation of lean mass. These data are the first to provide <i>in vivo</i> proof-of-concept for multi-pathway targeting in metabolic disease via a peptide hybrid, demonstrating that this approach is as effective as co-administration of individual peptides.</p> </div
Phybrid peptides induced greater weight loss compared to single peptide treatment and improved glycemic control similar to GLP-1 receptor agonism in obese diabetic <i>Lep<sup>ob</sup>/Lep</i><sup><i>ob</i></sup> mice.
<p>(<b>A</b>) Change in HbA1c, (<b>B</b>) change in plasma glucose, (<b>C</b>) total food intake, expressed as a percentage of vehicle, and (<b>D</b>) change in body weight following subcutaneous peptide infusion in leptin-deficient <i>Lep<sup>ob</sup>/Lep</i><sup><i>ob</i></sup> mice for 28 days. Groups not sharing the same superscript letter were significantly different from each other (p<0.05).</p